A composition may include at least one oligopeptide having solely alpha-peptide-bonds with one amino acid being cysteine (Cys), and free cysteine. A culture medium and may be used for culturing cells, preferably plant cells, animal cells, or mammalian cells, and a cell culture product may be manufactured using such a method.

The present invention discloses a serum-free medium for full suspension culture of MDCK cells and a preparation method of the serum-free medium. The serum-free medium for full suspension culture of the MDCK cells comprises basic metabolic nutrients, nucleotide, vitamins, inorganic salts, a shear force protective agent, a cell clustering resisting agent, a pH buffer agent, a pH indicator, an influenza virus proliferation accelerant and other additives. The preparation method of the serum-free medium for the full suspension culture of the MDCK cells comprises the following steps: 1) preparing a mixed solution: dissolving and mixing raw materials; and 2) regulating pH: regulating the pH of the mixed solution to 6.3 to 6.7, and setting a constant volume to obtain the serum-free medium for the full suspension culture of the MDCK cells. The medium supports the high-density full-suspension culture of the MDCK single cells, greatly shortens a time for educating the MDCK cells from adherent cells into the serum-free full suspension cells, and is applicable to the mass production of biological products, and particularly veterinary biological products.

The present disclosure provides methods for producing bioengineered tissue along with an apparatus and other relevant compositions employed in generation thereof.

Disclosed is a method for producing an antibody, comprising culturing in a presence of a polyanionic compound an animal cell into which a gene encoding an antibody has been introduced whereby the animal cell produces the antibody, wherein the polyanionic compound is at least one selected from the group consisting of an anionic polysaccharide and an anionic polyamino acid, and the antibody is an antibody in which at least 3 amino acid residues of framework region 3 (FR3) are substituted each independently with an arginine residue or a lysine residue.

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

The present invention relates to methods of modulating the mannose content of recombinant proteins.

A non-freezing refrigerated storage liquid for stem cells such as iPS cells, according to an embodiment, comprises: potassium ion species in a range of 30 to 80 mmoL/L; sodium ion species in a range of 30 to 80 mmoL/L, wherein ion-based molar ratio of sodium ion species to potassium ion species (ratio ofNa.sup.+ to K.sup.+) is in a range of 0.5 to 1.3; trolox or its analog at a concentration of 1 to 8 mM; adenine or a salt or derivative thereof at a concentration of 0.1 to 4.2 mM; all of or all but one, two or three of essential amino acids, total content of which is 50 to 200 mg; and non-essential amino acids, total content of which is 50 to 200 mg/L.

Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.

A method for stably amplifying a pluripotent stem cell comprises the following steps: (a) a cell implantation step: implanting pluripotent stem cells directly into a porous scaffold such that the porous scaffold contains 1×10.sup.4 or more of the pluripotent stem cells; and (b) a cell amplification step: immersing the porous scaffold in a specific culture medium which is xeno-free (XF) and performing amplification culture at an ambient temperature of 35.5-39.5° C. and a CO.sub.2 concentration of 5% to obtain the amplified pluripotent stem cells, wherein the amplified pluripotent stem cells aggregate to present an embryoid body state. The amplification method of the present disclosure can easily obtain an excellent effect of increasing an amplification multiple of the pluripotent stem cells to about 3 times or more.

Disclosed are improved compositions and methods for decreasing blood glucagon levels. As disclosed herein, L-glutamine is a selective stimulator of α-cell proliferation generated when glucagon signaling is interrupted. Therefore, disclosed is a method for treating a subject with hyperglucagonemia, e.g., a subject with diabetes, that involves administering to the subject a composition comprising an L-glutamine inhibitor in an amount effective to decrease blood glucagon levels.